Share on StockTwits

Shares of Amicus Therapeutics (NASDAQ:FOLD) were the recipient of unusually large options trading activity on Tuesday. Stock traders bought 5,148 put options on the company, Stock Ratings Network.com reports. This is an increase of approximately 533% compared to the typical volume of 813 put options.

A number of analysts have recently weighed in on FOLD shares. Analysts at Janney Montgomery Scott upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 1st. They now have a $5.00 price target on the stock, up previously from $2.50. Separately, analysts at Leerink Swann upgraded shares of Amicus Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 1st. They now have a $6.00 price target on the stock, up previously from $2.50. Finally, analysts at JPMorgan Chase & Co. upgraded shares of Amicus Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, June 30th.

Amicus Therapeutics (NASDAQ:FOLD) traded up 0.44% during mid-day trading on Tuesday, hitting $4.57. The stock had a trading volume of 1,155,568 shares. Amicus Therapeutics has a 1-year low of $1.77 and a 1-year high of $4.74. The stock has a 50-day moving average of $4.07 and a 200-day moving average of $2.80. The company’s market cap is $359.7 million.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.08. Analysts expect that Amicus Therapeutics will post $-0.94 EPS for the current fiscal year.

Amicus Therapeutics, Inc (NASDAQ:FOLD) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.